David R Hudgens, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-3220 Fax: 423-844-3114 |
Dr. Michael Wayne Rentz, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-3220 Fax: 423-844-3114 |
Don E Asberry, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-3220 Fax: 423-844-3114 |
News Archive
In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.
Many factors, including need, affect healthcare use. Strategies geared to enhancing the provision and access to healthcare must consider the various mechanisms that contribute to healthcare need and use.
› Verified 6 days ago